GMAB revenueFY2025$3.72B
- FY YoY
- +19.2%
GMAB revenue was $3.72B for fiscal 2025 (ended Dec 31, 2025), up 19.2% from fiscal 2024.
Genmab A/S (GMAB) financials
For fiscal 2025 (ended Dec 31, 2025), Genmab A/S reported $3.72B of revenue and $963.00M of net income.
- Revenue, FY2025
- $3.72B
- Revenue growth, YoY
- +19.2%
- Net income, FY2025
- $963.00M
- Net income growth, YoY
- -15.0%
- Net margin
- 25.9%
- Free cash flow, FY2025
- $1.15B
- EPS, diluted, FY2025
- $15.37
- EPS growth, YoY
- -12.3%
- Cash
- $1.72B
- Total debt
- $5.27B
- P/E
- 34.75
- P/S
- 9.00
- Market cap
- $33.47B
FY2023FY2025
FY2023FY2025
FY2023FY2025
GMAB revenue and earnings growth
GMAB net incomeFY2025$963.00M
- FY YoY
- -15.0%
GMAB net income was $963.00M for fiscal 2025 (ended Dec 31, 2025), down 15.0% from fiscal 2024.
GMAB EPSFY2025$15.37
- FY YoY
- -12.3%
GMAB diluted EPS was $15.37 for fiscal 2025 (ended Dec 31, 2025), down 12.3% from fiscal 2024.
GMAB free cash flowFY2025$1.15B
- FY YoY
- +4.5%
GMAB free cash flow was $1.15B for fiscal 2025 (ended Dec 31, 2025), up 4.5% from fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $3.72B | $3.12B | $2.39B |
| Cost of revenue | $238.00M | $143.00M | $33.00M |
| Gross profit | $3.48B | $2.98B | $2.36B |
| Research and development | $1.61B | $1.41B | $1.11B |
| Selling, general and admin | $626.00M | $549.00M | $478.00M |
| Operating income | $1.06B | $972.00M | $772.00M |
| Interest expense | $269.00M | $291.00M | $254.00M |
| Pre-tax income | $1.20B | $1.33B | $817.00M |
| Income tax | $241.00M | $193.00M | $186.00M |
| Net income | $963.00M | $1.13B | $631.00M |
| EPS, basic | $15.50 | $17.66 | $9.67 |
| EPS, diluted | $15.37 | $17.53 | $9.58 |
| Diluted shares | 62.7M | 64.7M | 65.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.72B | $1.38B | $2.20B |
| Receivables | $1.11B | $923.00M | $733.00M |
| Inventory | $18.00M | $9.00M | $8.00M |
| Current assets | $2.88B | $3.90B | $4.91B |
| Goodwill | $355.00M | $355.00M | $0 |
| Total assets | $12.87B | $6.41B | $5.23B |
| Current liabilities | $1.43B | $744.00M | $368.00M |
| Short-term debt | $273.00M | $0 | $0 |
| Long-term debt | $5.00B | $0 | $0 |
| Total debt | $5.27B | $0 | $0 |
| Total liabilities | $7.03B | $1.28B | $545.00M |
| Shareholders' equity | $5.85B | $5.14B | $4.69B |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $1.19B | $1.13B | $1.07B |
| Capital expenditures | $37.00M | $27.00M | $53.00M |
| Free cash flow | $1.15B | $1.10B | $1.02B |
| Investing cash flow | -$5.64B | -$1.45B | -$185.00M |
| Financing cash flow | $4.79B | -$566.00M | -$89.00M |
| Stock-based compensation | $128.00M | $105.00M | $85.00M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | 19.2% | 30.6% | - |
| Net income growth, YoY | -15.0% | 79.6% | - |
| EPS growth, YoY | -12.3% | 83.0% | - |
| Gross margin | 93.6% | 95.4% | 98.6% |
| Operating margin | 28.6% | 31.1% | 32.3% |
| Net margin | 25.9% | 36.3% | 26.4% |
| Free cash flow margin | 30.9% | 35.2% | 42.6% |
| Return on equity | 16.5% | 22.1% | 13.5% |
| Return on assets | 7.5% | 17.7% | 12.1% |
| Current ratio | 2.02 | 5.24 | 13.35 |
| Debt to equity | 0.90 | 0.00 | 0.00 |
Source: XBRL data Genmab A/S files with the SEC, latest filing dated Feb 17, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
GMAB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GMAB | $3.72B | +19.2% | $963.00M | 25.9% | $33.47B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
GMAB FAQ
9 questionsWhat is GMAB revenue?
Genmab A/S (GMAB) reported $3.72B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 19.2% from the year before.Is GMAB profitable?
Yes. Genmab A/S earned $963.00M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 25.9%.How much cash and debt does GMAB have?
Genmab A/S reported $1.72B in cash and cash equivalents and $5.27B of debt on its most recent balance sheet in SEC filings.How fast is GMAB revenue growing?
Genmab A/S's revenue changed +19.2% in fiscal 2025, to $3.72B.What is GMAB gross margin?
Genmab A/S's gross profit was $3.48B on $3.72B of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 93.6%.What is GMAB free cash flow?
Genmab A/S generated $1.15B of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of $1.19B less capital expenditures.What is GMAB earnings per share?
Diluted earnings per share were $15.37 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did GMAB last report financial results?
The latest statements here come from Genmab A/S's 20-F filed on Feb 17, 2026, covering the period ended Dec 31, 2025.Where does this GMAB financial data come from?
Quantisnow builds these statements from the structured XBRL data Genmab A/S files with the SEC. It is provided for information only and is not investment advice.